Peter A. Altman, Ph.D. has served as our President and Chief Executive Officer since 2002, where he has global responsibility for the development, manufacture and marketing of our therapeutic candidates and products. He was founding Chief Executive Officer from 1999 to 2003 and board member of CareDx, a developer of a gene based diagnostics to be used in chronic inflammatory diseases, including cardiac transplantation, coronary artery disease and systemic lupus erythematosus. He was also founding Chief Executive Officer for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association. He has over 27 years of experience in life science research and product development, is named inventor in 40 U.S. patents, and has authored 38 scientific publications in cardiology, ophthalmology and spine.
Eric Duckers, MD, PhD, FESC has served as Chief Medical Officer since 2016. He has over 19 years of experience in cardiovascular research, is named inventor in 10 U.S. patents, and has authored 140 scientific publications in cardiology, neurology and cell biology. Dr. Duckers studied Medicine and Pharmacy at the University of Utrecht, as well as Management in Health Care (Univ.Rotterdam). From 1992-1993 he completed his PhD thesis at the Rudolf Magnus Institute for NeuroScience, Cum Laude, and obtained a registration as clinical pharmacologist. He was trained as an interventional cardiologist at the Thoraxcenter Rotterdam. Here, he supervised the molecular cardiology program and initiated and supervised several international research consortia, as well as several international multicentered clinical trials, related to interventional cardiology, stem cell therapy, and biomarkers. In addition, he initiated and led several spin-off companies based on IP generated from the research programs.
David McClung has served as our Vice President of Finance since 2016 and has been with the company since September 2013. Mr. McClung has more than 20 years of finance and accounting experience in publicly and privately financed organizations, including startup enterprises, middle-market businesses and large public companies. For the last ten years he has held leadership roles in emerging businesses, primarily life science ventures, most recently as the Controller for Sonitus Medical Inc. and NextWave Pharmaceuticals, Inc. He spent his early career in public accounting, beginning with KPMG LLP, after which he gained broad financial and operational experience directing the North American audit group for The Clorox Company and serving as Director of Internal Audit for Matson Navigation, Inc. Mr. McClung earned a Bachelor of Arts degree in Accounting from Georgia State University, graduating with honors. He is an actively licensed CPA and member of the AICPA and the California Society of CPAs.
Andrew Mackenzie has served as consulting Vice President of Regulatory since 2015 and has been with BioCardia for nine years. He was previously Vice President of Research & Development at StemCor Systems, where he was responsible for the initial product development efforts. Previously, Mr. Mackenzie was head of Quality, Clinical and Regulatory Affairs at Sadra Medical, a start-up company focused on percutaneous delivery of a replacement aortic heart valve, General Manager at Perfect Surgical, a Palo Alto based start-up company developing a novel electro-surgical device, Director of Research and Development at InnerDyne Medical, a maker of minimally invasive surgery products, and Technical Project Leader at Guidant Corporation, a maker of products for the treatment of cardiovascular disease. Mr. Mackenzie received his Master of Business Administration from Santa Clara University, his Master of Science in Mechanical Engineering from the University of California at Berkeley, his Bachelor of Science in Mechanical Engineering from Cal Poly, San Luis Obispo, and has over 20 years of engineering and management experience in large and small companies.
Phil Pesta has served as our Vice President, Operations since July 2011. Mr. Pesta has over 20 years of experience in the medical device industry, primarily in manufacturing and operations roles. Before joining our company, Mr. Pesta was with Boston Scientific. He was most recently responsible for developing and managing the operations transfer plan for the divestiture of their neurovascular division to Stryker Corporation. Prior to that, Mr. Pesta held simultaneous roles as Director of Engineering at Boston Scientific’s electrophysiology division and Plant Manager at the embolic protection division. Earlier in his career, Mr. Pesta held positions in management, project management and manufacturing engineering at other companies including Conceptus, Novare Surgical Systems, Medtronic Anneurx and Modified Polymer Components. He has facilitated the commercial launch of multiple products and is listed as an inventor on three U.S. patents. Mr. Pesta earned a Bachelor of Arts Degree in General Design Studies from San Jose State University.
Rick Allen joined BioCardia in 2015 as our Vice President of Quality Assurance. Rick has responsibility for regulatory compliance of our quality system and oversight of the manufacturing and product development quality engineering and quality control functions. He was Director of Quality Affairs at Hansen Medical prior to joining BioCardia. Rick has over 30 years of experience in medical devices companies in a variety of roles including product development, technology development, manufacturing and quality roles. His medical device experience includes surgical devices, vascular catheters, implantable coronary and peripheral stents, and drug eluting stents. He has also worked with startups to support product development, initial production startup, creation of appropriate quality systems and to gain quality system certification. Rick earned his Bachelor of Science in Bioengineering from Texas A&M University and an executive MBA from the Fuqua School of Business, Duke University.